MarketsandMarkets Blog

The Global Pharmaceutical Contract Development Market in terms of revenue was estimated to be worth $176.5 billion in 2023 and is poised to reach $258.3 billion by 2028, growing at a CAGR of 7.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference...

The Global Pharmaceutical Contract Development Market in terms of revenue is expected to be worth $171.3 billion by 2026, growing at a CAGR of 7.3% in the upcoming years. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders,...

Introduction to the Pharmaceutical Contract Development Market The pharmaceutical contract development market refers to the outsourcing of drug development services to external organizations. This includes the research, development, and manufacture of new medicines and drugs. It is a rapidly growing sector of the pharmaceutical industry, with the global market expected to expand at a compound annual growth rate of 6.2% between 2020 and 2027. Companies that contract out services are able to reduce costs, increase efficiency, and access specialized expertise. Contract development organizations (CDOs) provide a variety of services, such as analytical testing, preclinical studies, clinical trials, and manufacturing. This market is expected to continue to grow in the future, with an increasing demand for outsourcing services from pharmaceutical companies. Overview of the Pharmaceutical Contract Development Industry The pharmaceutical contract development industry is a rapidly growing field, driven by the demand for custom drug development and the need to reduce costs associated with in-house drug development. Contract development organizations (CDOs) provide a variety of services to pharmaceutical and biotechnology companies, including drug discovery and development, preclinical and clinical trial design and management, and regulatory affairs. CDOs provide services such as formulation development, analytical chemistry, process chemistry and scale-up, drug substance and drug product manufacturing, and packaging and labeling. CDOs also provide expertise in fields such as regulatory affairs and pharmacovigilance. As the pharmaceutical industry continues to expand, CDOs are becoming increasingly important in providing specialized services to the drug development process. Factors Driving Growth in the Pharmaceutical Contract Development Industry Increasing Demand for Outsourcing: Pharmaceutical companies are increasingly outsourcing their contract development and manufacturing operations (CDMOs) to third-party providers, which has been a major driver of the industry’s growth. This is due to the cost savings and access to expertise that outsourcing provides. Shorter Timeframe for Drug Development: The time required to develop a new drug has decreased due to advancements in technology such as high-throughput screening, artificial intelligence and computer-aided drug design. This has increased the demand for CDMOs who can provide the necessary services in a shorter timeframe. Regulatory Changes: The implementation of regulations such as the Drug Supply Chain Security Act (DSCSA) has created a need for CDMOs who are compliant with these regulations. This has further increased the demand for CDMOs. Growth in Biologics: The biologics market is growing rapidly due to the introduction of new biologic drugs. This has increased the demand for CDMOs who can provide services related to the development and manufacture of biopharmaceuticals. Increasing Complexity of Generics: The complexity of generic drugs has increased over the years, creating a need for CDMOs who can provide services related to the development and manufacture of these drugs. Key Players in the Pharmaceutical Contract Development Market The...